PMID: 8997461Jan 1, 1997Paper

Mexiletine in the symptomatic treatment of diabetic peripheral neuropathy

The Annals of Pharmacotherapy
J M WrightL Graves

Abstract

To evaluate the efficacy and safety of mexiletine in the symptomatic treatment of diabetic peripheral neuropathy (DPN). In this prospective, double-blind study, 29 patients were randomized to receive mexiletine 600 mg/d or matching placebo for 3 weeks. A four-item symptom score (FIS), which rated pain, dysesthesias, paresthesias, and nightly exacerbations of symptoms, and a 100-mm visual analog scale (VAS), which rated pain intensity, were completed by patients before and after treatment. At the end of treatment independent patient and investigator global assessments were made. Patients reported adverse effects after 1 and 3 weeks of treatment. Treatment groups were similar at baseline. The difference between the median changes in FIS scores (mexiletine = 5.5, placebo = 2) was not statistically significant. Overall symptom response was similar in both treatment groups as demonstrated by both global assessments (p = 0.19). The mean change in VAS score from baseline to posttreatment was determined for both groups and the difference between these mean scores was 16.5 mm (95% CI, -7.1 to 40.2 mm) (p = 0.16). Inadequate statistical power (1-beta = 0.40) may have resulted from small sample size, small magnitude of effect, or variabil...Continue Reading

References

Dec 1, 1992·Diabetes Care·A I VinikL B Colen
Nov 1, 1992·Diabetes Care·H StrackeK Federlin
Mar 1, 1992·The Annals of Pharmacotherapy·R L Cody, M K Slack
May 7, 1992·The New England Journal of Medicine·M B MaxR Dubner
Apr 1, 1986·Drug Intelligence & Clinical Pharmacy·B J Schrader, J L Bauman
Apr 1, 1989·Annals of Internal Medicine·J R WoodsM Tavel
Apr 1, 1995·Diabetes Care·D GiuglianoF D'Onofrio
Sep 30, 1993·The New England Journal of Medicine·UNKNOWN Diabetes Control and Complications Trial Research GroupC Siebert
Apr 1, 1996·Annals of Emergency Medicine·K H Todd

❮ Previous
Next ❯

Citations

Aug 22, 2001·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·V Bril
Dec 12, 2001·Drugs & Aging·P G Jensen, J R Larson
Sep 28, 2002·Current Opinion in Neurology·Zachary Simmons, Eva L Feldman
Dec 24, 2002·Drugs & Aging·Mahmood Ahmad, Charles Roger Goucke
Dec 1, 2005·Current Diabetes Reports·Roy Freeman
Feb 21, 2007·Pain Practice : the Official Journal of World Institute of Pain·Kenneth C Jackson
Mar 6, 2007·Diabetic Medicine : a Journal of the British Diabetic Association·V M JoseP Pandhi
Nov 11, 2009·Diabetic Medicine : a Journal of the British Diabetic Association·D BansalP Dutta
Jun 30, 2011·The American Journal of Hospice & Palliative Care·Raj Mitra, Stephanie Jones
Nov 7, 2019·The Cochrane Database of Systematic Reviews·Vidya ChallapalliDaniel B Carr
Mar 17, 2001·Current Pain and Headache Reports·M S Wallace
Mar 7, 2012·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·M Soledad CepedaD Russell Wada
Jun 6, 2013·Oxidative Medicine and Cellular Longevity·Asieh Hosseini, Mohammad Abdollahi
May 2, 2003·Current Pain and Headache Reports·Richard BarbanoRobert H Dworkin
Sep 7, 1999·Diabetic Medicine : a Journal of the British Diabetic Association·S J BenbowI A MacFarlane
Apr 22, 2004·The Clinical Journal of Pain·Ahmad BeydounEnrique J Carrazana
Mar 28, 2003·The New England Journal of Medicine·Jerry R Mendell, Zarife Sahenk
Nov 14, 2008·Expert Opinion on Pharmacotherapy·Mitra Tavakoli, Rayaz A Malik
Nov 3, 2004·The Neurologist·Clifton Gooch, David Podwall
Dec 1, 2003·Journal of Clinical Neuromuscular Disease·Thomas H Brannagan
Sep 6, 2005·CNS Spectrums·Roy Freeman
Oct 1, 2009·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Anindya BhattacharyaSandra R Chaplan
Nov 13, 2003·Current Diabetes Reports·Singhan T M Krishnan, Gerry Rayman
Oct 20, 2005·The Cochrane Database of Systematic Reviews·V ChallapalliD B Carr
Nov 5, 2020·Pain and Therapy·Andreas LiampasPanagiotis Zis
Sep 1, 2004·Clinical Therapeutics·Mike NamakaJoanne Major
Aug 1, 2020·Current Drug Safety·Johan RøikjerNiels Ejskjaer

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.